title: New antithrombotic agents for the prevention and treatment of deep vein thrombosis.
abstract: Besides low molecular weight heparins (LMWHs) a number of new antithrombotic agents have been evaluated mainly in the prevention of deep vein thrombosis (DVT) and, to a lesser extent, in the treatment of established DVT. They include the Pentasaccharide, a synthetic ultra LMWH, Dermatan Sulphate, a glycosaminoglycan which activates heparin cofactor II, Orgaran, a mixture of Heparan and of Dermatan Sulphate, Hirulog and Hirudin, two direct thrombin inhibitors. The efficacy and safety of these compounds have been studied in comparison with a placebo or with unfractionated heparin but not with LMWH which is considered as a gold standard for these clinical indications. It is thus difficult at present to appreciate the advantages of these new antithrombotic agents over conventional LMWH therapy.
authors.affiliation: Laboratoire de Recherche sur l'Hémostase et la Thrombose Toulouse, France.
authors.forename: B
authors.initials: B
authors.lastname: Boneu
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use; D000990:Antithrombin III / Q000737:chemistry / Q000378:metabolism; D001665:Binding Sites; D002809:Chondroitin Sulfates / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003871:Dermatan Sulfate / Q000627:therapeutic use; D004353:Drug Evaluation, Preclinical; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006493:Heparin / Q000737:chemistry / Q000378:metabolism / Q000627:therapeutic use; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006497:Heparan Sulfate / Q000627:therapeutic use; D006801:Humans; D015337:Multicenter Studies as Topic; D009844:Oligosaccharides / Q000627:therapeutic use; D011183:Postoperative Complications / Q000517:prevention & control; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000517:prevention & control*; D012008:Recurrence; D013917:Thrombin / Q000037:antagonists & inhibitors; D013924:Thrombophlebitis / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D000990:Antithrombin III; D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D065427:Factor Xa Inhibitors; D005343:Fibrinolytic Agents; D006493:Heparin; D006495:Heparin, Low-Molecular-Weight; D006497:Heparan Sulfate; D009844:Oligosaccharides; D013917:Thrombin; C064764:PENTA; C035838:danaparoid